Home Authors Posts by Rick Powers

Rick Powers

Avatar photo
Rick Powers' 35 years in Biotech and 20 years in ADCs have given him a unique perspective on the industry. After UC Davis, Rick joined Hybritech in Torrey Pines (1985) as an early conjugation pioneer with hetero-bifunctional chemistry. Later work in Irv Weissman’s SyStemix led him to Coulter Pharmaceutal in SSF, CA, (1999) where we worked with King, Bebbington, and Yarrington (of Celltech Mylotarg fame) to conjugate early cc-1065 payloads. Rick moved across the street to Eos Biotechnology (2000) to help Dave Martin with his very early Seattle Genetics ADC R&D agreement. Rick received one of the first deliveries of vc-MMAE from Damon Meyer and Peter Senter in 2001. Eos Biotech was bought by Protein Design Labs which later morphed into Facet Biotech to be sold to Abbott Laboratories (2010), which spun out Abbvie as a $22B start up company in 2013. Rick’s last 8 years at Abbvie/Abbott gave great experience with two drugs in humans trials, including StemCentrx ADC process development work. Rick managed the entire Abbvie Bioconjugation lab in Redwood City and operated as an “internal CMO” and trainer to the entire Abbvie organization, including North Chicago, IL and Worcester, MA. Rick is currently consulting to select clients, and was an invited expert speaker at the World ADC San Diego 2018, Shanghai, China 2019, and San Diego 2019. He will be speaking at the WADC London 2020 conference. He gives the three-hour “Workshop A- Advanced Design of ADCs: Principles and Applications using next generation linkers and site specific technology”. With extensive knowledge of the latest industry trends, Rick has extensive experience in antibody drug conjugate (ADC) technology, including novel drug linker screening, analytical testing methods, bi-functional ADC constructs, bioconjugation process development and manufacturing scale-up. Rick lives and works in Palo Alto, California